Monitor stockholder vote on the share exchange and the filing of the S-1 registration statement and proxy statement. Key catalysts include the NucleoCapture sepsis interim analysis (Q4 2027) and the DNase LBCL proof-of-concept data (Q2 2027). The combined company's cash runway and ability to fund multiple pivotal trials without additional capital will be critical.
Price Chart
Executive Summary
Xenetic Biosciences filed an updated investor presentation detailing its proposed reverse merger with Santersus AG, where Santersus shareholders will own ~85% of the combined company. The presentation highlights Santersus' NET-targeting platforms (NucleoCapture and DNase) with two FDA Breakthrough Device Designations and a pipeline targeting sepsis, SLE, liver transplantation, and large B-cell lymphoma. The transaction is expected to close in Q4 2026, with the combined company trading under the ticker SNTS.
Key Facts
- Definitive Share Exchange Agreement signed September 14, 2026, with closing expected in Q4 2026
- Santersus shareholders to own ~85% of combined company; pre-merger Xenetic stockholders ~15%
- Santersus valued at $120 million; Xenetic valued at $21 million (assumes $0 Net Cash); total pro-forma valuation $141 million
- Combined company to trade on Nasdaq under ticker SNTS
- Santersus has two FDA Breakthrough Device Designations for NucleoCapture in sepsis and SLE
- NucleoCapture sepsis pivotal study (up to 350 patients) ongoing; first interim analysis expected Q4 2027; EU market launch target Q2 2028
- NucleoCapture SLE pivotal study (up to 110 patients) to start Q1 2027; interim analysis Q4 2027
- DNase investigator-initiated study in large B-cell lymphoma with CAR T cells enrolling 12 patients; proof-of-concept data expected Q2 2027
- Positive compassionate-use data: 100% 7-day survival in 10 sepsis patients; 54% reduction in SLEDAI-2K in 10 SLE patients
- Xenetic had 2,343,181 shares outstanding as of July 31, 2026; pro-forma fully diluted shares ~17,099,265
Financial Impact
Transaction values Santersus at $120M and Xenetic at $21M, for a combined pro-forma valuation of $141M. No revenue or earnings figures disclosed.
Risk Factors
- Transaction may not close if Xenetic stockholders do not approve or if Nasdaq listing conditions are not met
- Clinical development risks: NucleoCapture sepsis pivotal trial may fail to meet composite endpoint (mortality + organ support-free days)
- Combined company will need additional capital to fund ongoing clinical programs; no current revenue
- Reverse stock split may be required to maintain Nasdaq listing
- Integration risk and potential management distraction during transaction closing
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-007340 |
| Document: xenetic_8k.htm | 0001683168-26-007340 |
| Document: 0001683168-26-007340-index-headers.html | 0001683168-26-007340 |
| Document: 0001683168-26-007340-index.html | 0001683168-26-007340 |
| Document: 0001683168-26-007340.txt | 0001683168-26-007340 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | 8-K | $2.47 $1.93 | ▼ −21.86% | ▼ −21.44% | $1.79 (−27.53%) |
Sep 18, 2026 5w ago | SC 13G | $2.77 $1.99 | ▼ −28.16% | ▼ −28.36% | $1.79 (−35.38%) |
Sep 16, 2026 5w ago | 8-K | $2.19 $2.10 | ▼ −4.11% | ▼ −7.29% | $1.79 (−18.26%) |
Aug 7, 2026 11w ago | 8-K | $3.17 $4.67 | ▲ +47.32% | ▲ +47.72% | $1.79 (−43.53%) |
May 13, 2026 23w ago | 8-K | $3.18 $3.00 | ▼ −5.66% | ▼ −5.05% | $1.79 (−43.71%) |
Apr 24, 2026 26w ago | 10-K/A | $3.03 $3.07 | ▲ +1.18% | ▼ −3.77% | $1.79 (−40.92%) |
Apr 24, 2026 26w ago | 8-K | $3.03 $3.07 | ▲ +1.18% | ▼ −3.77% | $1.79 (−40.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers